These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27185772)

  • 1. T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy.
    Heijink DM; Kater AP; Hazenberg MD; Hagenbeek A; Kersten MJ
    Neth J Med; 2016 May; 74(4):147-51. PubMed ID: 27185772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
    Lorentzen CL; Straten PT
    Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current status and future development of CAR-T gene therapy].
    Ozawa K
    Rinsho Ketsueki; 2015 Oct; 56(10):2180-5. PubMed ID: 26458458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies.
    Jain MD; Davila ML
    Stem Cells; 2018 Jan; 36(1):36-44. PubMed ID: 29024301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
    Atanackovic D; Radhakrishnan SV; Bhardwaj N; Luetkens T
    Br J Haematol; 2016 Mar; 172(5):685-98. PubMed ID: 26791002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building blocks for institutional preparation of CTL019 delivery.
    McGuirk J; Waller EK; Qayed M; Abhyankar S; Ericson S; Holman P; Keir C; Myers GD
    Cytotherapy; 2017 Sep; 19(9):1015-1024. PubMed ID: 28754600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cells merge into the fast lane of cancer care.
    Frey NV; Porter DL
    Am J Hematol; 2016 Jan; 91(1):146-50. PubMed ID: 26574400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of chimeric antigen receptor therapy for haematological malignancies.
    Maude S; Barrett DM
    Br J Haematol; 2016 Jan; 172(1):11-22. PubMed ID: 26560054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
    Gill S; June CH
    Immunol Rev; 2015 Jan; 263(1):68-89. PubMed ID: 25510272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical translational research of chimeric antigen receptor-T (CAR-T) cells for the treatment of relapsed and refractory B-cell lymphoma/leukemia].
    Yuan SZ; Su H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1137-41. PubMed ID: 25130844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
    Magee MS; Snook AE
    Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.
    Levine BL
    Cancer Gene Ther; 2015 Mar; 22(2):79-84. PubMed ID: 25675873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR therapy: the CD19 paradigm.
    Sadelain M
    J Clin Invest; 2015 Sep; 125(9):3392-400. PubMed ID: 26325036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
    Gross G; Eshhar Z
    Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel therapy for malignant lymphoma: adoptive immuno-gene therapy using chimeric antigen receptor(CAR)-expressing T lymphocytes].
    Ozawa K
    Nihon Rinsho; 2014 Mar; 72(3):547-52. PubMed ID: 24724418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.